Multiple myeloma (MM) is a rapidly fatal plasma-cell malignancy that evolves mainly in the bone marrow. Melphalan is widely used to treat patients with MM but as yet its mechanisms of action are poorly documented. In the current study, we demonstrate that melphalan induces a drastic downregulation of Mcl-1L, Bcl-x L and BimEL in human melphalan-sensitive myeloma cells while the most potent proapoptotic isoforms, BimL and S, are affected to a lesser extent. Moreover, Mcl-1L and BimEL disappearance is associated with the generation of proapoptotic cleaved forms generated by a caspase cleavage. In myeloma cells, we have previously shown that Mcl-1 neutralizes the proapoptotic function of Bim and therefore, prevents the activation of death effectors. In this study, we demonstrate that melphalan disrupts the Mcl-1/ Bim complex whereas the Bcl-2/Bim complex is not modified. The disappearance of full length Mcl-1 allows the release of Bim isoforms, particularly L and S, which can exert their proapoptotic function and leads to Bax activation and cytochrome c release. Thus, we can hypothesize that the cleaved 26 kDa proapoptotic Mcl-1 and the 19 and 12 kDa of Bim, generated during melphalan treatment could contribute to the amplification loop of apoptosis.
Multiple myeloma (MM) is a rapidly fatal plasma-cell malignancy that evolves mainly in the bone marrow. Melphalan is widely used to treat patients with MM but as yet its mechanisms of action are poorly documented. In the current study, we demonstrate that melphalan induces a drastic downregulation of Mcl-1L, Bcl-x L and BimEL in human melphalan-sensitive myeloma cells while the most potent proapoptotic isoforms, BimL and S, are affected to a lesser extent. Moreover, Mcl-1L and BimEL disappearance is associated with the generation of proapoptotic cleaved forms generated by a caspase cleavage. In myeloma cells, we have previously shown that Mcl-1 neutralizes the proapoptotic function of Bim and therefore, prevents the activation of death effectors. In this study, we demonstrate that melphalan disrupts the Mcl-1/ Bim complex whereas the Bcl-2/Bim complex is not modified. The disappearance of full length Mcl-1 allows the release of Bim isoforms, particularly L and S, which can exert their proapoptotic function and leads to Bax activation and cytochrome c release. Thus, we can hypothesize that the cleaved 26 kDa proapoptotic Mcl-1 and the 19 and 12 kDa of Bim, generated during melphalan treatment could contribute to the amplification loop of apoptosis. Multiple myeloma (MM) is an incurable disease characterized by an accumulation of malignant longlived plasma cells within the bone marrow. Dysregulation of the apoptotic pathway is crucial in this pathology and subsequent chemoresistance in MM. Bcl-2 family proteins are central regulators of apoptosis subdivided into antiapoptotic and proapoptotic members (Gross et al., 1999; Cory et al., 2003) . BH3-only proteins are now considered as essential initiators of apoptotic cell death (Huang and Strasser, 2000) . Among the BH3-only proteins we recently demonstrated that myeloma cells strongly expressed the three major isoforms of Bim:
BimEL, BimL and BimS (Gomez-Bougie et al., 2004) . All three isoforms have proapoptotic activity, BimS being the most potent (O'Connor et al., 1998) . Bim has been shown to be involved in lymphoid homeostasis and in cytokine-dependent survival pathways (Bouillet et al., 1999) . Mcl-1, an antiapoptotic Bcl-2 family protein is involved in the maintenance of T and B cells and is required at cytokine dependent stages (Opferman et al., 2003) . Indeed, the role of Mcl-1 can be explained by its selective sequestration of Bim, which kept it in check (Ofperman et al., 2003) . We and others have shown that Mcl-1 is an essential survival protein in myeloma cells (Derenne et al., 2002; Zhang et al., 2002; Jourdan et al., 2003) . Indeed, in myeloma cells, Mcl-1 neutralizes the proapoptotic function of Bim and prevents the activation of death effectors (Gomez-Bougie et al., 2004 Glucocorticoids such as dexamethasone are mostly used in combination with chemotherapy agents in the treatment of MM. Among these, melphalan is the most commonly used (Moreau et al., 2002) . Thus, we have investigated the mechanisms of apoptosis induction by melphalan in myeloma cells.
A pharmacokinetic study of patients with MM receiving melphalan has previously shown that a concentration of 20 mM was in the range of the therapeutical concentrations. Thus, we investigated the effect of melphalan in two MM derived cell lines, that is, MDN and NCI-H929. Melphalan induces significant apoptosis (7471% apoptotic cells) in MDN cells after 24 h of treatment whereas it has a weak effect in NCI-H929 cells (1474% apoptotic cells). Therefore, we compared the effect of 24 h melphalan treatment on antiapoptotic (Mcl-1, Bcl-2 and Bcl-x L ) and proapoptotic protein expression. Melphalan induced a dramatic downregulation of the full-length Mcl-1 and Bcl-x L in MDN cells whereas it had no effect on these proteins in resistant NCI-H929 cells (Figure 1) . Bcl-2 level remains unchanged in both cell lines. Mcl-1 has PEST sequences, which could explain its short half life and its degradation by the proteasome pathway (Craig, 2002; Michels et al., 2005) . To determine whether full-length Mcl-1 and Bcl-x L downregulation induced by melphalan is the result of proteasome degradation, MDN cells were treated with melphalan and a proteasome inhibitor (lactacystin 10 mM) for 24 h. Neither full-length Mcl-1 nor Bcl-x L downregulation was reversed by this inhibitor, suggesting that the disappearance of both antiapoptotic proteins was not due to proteasome degradation. The major three isoforms of Bim (EL, L and S) are expressed in both cell lines. Of note, melphalan mainly downregulated BimEL in MDN cells while it has no effect on BimEL expression in NCI-H929 cells. Again, BimEL downregulation is independent of the proteasome pathway since the addition of lactacystin did not inhibit BimEL decrease (Figure 1 ). The disappearance of BimEL and the decrease of BimL and S induced by melphalan correlated with the appearance of two new bands of 19 and 12 kDa, suggesting a cleavage of Bim isoforms.
Recently, a caspase dependent cleavage of Mcl-1 has been described (Snowden et al., 2003; Herrant et al., 2004; Michels et al., 2004) and the generated cleaved forms are specifically recognized by the antibody antiMcl-1 S-19. Indeed, using this antibody we detected in control cells, not only Mcl-1L but also two other bands of around 28 and 26 kDa, respectively (Figure 2a) . The 28 kDa band may correspond to Mcl-1S whereas the 26 kDa band could be the result of a cleavage of Mcl-1 (Snowden et al., 2003; Herrant et al., 2004; Michels et al., 2004) . Indeed, MDN cells treated by melphalan during 8 h presented a significant down-regulation of Mcl-1L, an accumulation of the 26 kDa band and the appearance of a weak 16 kDa band, suggesting that ) were resuspended in 150 ml lysis buffer (10 mM Tris, pH 7.6, 150 mM NaCl, 5 mM EDTA and 1% Triton X-100) containing 2 mM PMSF and 2 mg/ml aprotinin. After 40 min on ice, lysates were cleared by centrifugation at 12 000 g for 30 min at 41C. An amount of 70 mg of protein per lane were separated by SDS-PAGE, then electrotransferred onto PVDF membranes. (Oliver et al., 2000) . An amount of 50 mg mitochondrial or cytosolic fraction (S100) were separated in 15% SDS-PAGE. The presence of cytochrome c was revealed using a monoclonal anticytochrome c (BD-Bioscience Pharmingen, France, clone 7H8.2C12)
Mcl-1L is rapidly cleaved. To determine whether caspases are involved in Mcl-1 and Bim cleavage, we preincubated MDN cells with the pan-caspase inhibitor zVADfmk before melphalan treatment. This inhibitor prevented the disappearance of both Mcl-1L and Bcl-x L and the downregulation of BimEL (Figure 2a) . Furthermore, it abolished the generation of Mcl-1 cleaved bands as well as the two new bands of Bim. We can hypothesize that the absence of a cleaved product of Bcl-x L is due to an impairment of recognition by the antibody, which is documented for the anti-Mcl-1 antibody used in this study (Figure 1) . These results indicate that melphalan induces Mcl-1L, Bcl-x L, BimEL cleavage by caspase activation. Concomitant to these cleavages, we observed the generation of the active p17 caspase 3 cleaved form (result not shown), the activation of the proapoptotic protein Bax as shown by the exposure of an occluded N-terminal sequence (Figure 2b ) and the release of cytochrome c (Figure 2c ). We could hypothesize that activated caspases such as those generated by an endoplasmic reticulum stress may act upstream of the Bim/Mcl-1 complex (Morishima et al., 2002) . However, caspase activation could mediate as well a mitochondrial amplification loop. Indeed, it has been shown that druginduced apoptosis of B lymphoid cells is associated with caspase 8 and 3 activation secondarily to cytochrome c release (von Haefen et al., 2003) . Lately, caspase 2 processed downstream of the mitochondria has been also involved in this amplification loop (Schmelz et al., 2004) . Interestingly, it has been documented for some anti-and proapoptotic proteins that caspase cleavage leads to a positive feedback of the apoptotic signal (Clem et al., 1998; Snowden et al., 2003; Chen and Zhou, 2004; Herrant et al., 2004; Michels et al., 2004; Michels et al., 2005) . Therefore, melphalan could not only be able to deprive cells of the antiapoptotic signal but it could also generate additional proapoptotic mediators.
In T and B cells, the proapoptotic activity of Bim seems to be controlled by its sequestration by the antiapoptotic Bcl-2 relatives on the mitochondria rather than by its interaction with the microtubules (Zhu et al., 2004; Gomez-Bougie et al., 2005) . We have previously shown that Mcl-1 and Bim are endogeneously associated in MM and that regulation of this complex is critical for MM survival (Gomez-Bougie et al., 2004) . Thus, we investigated by coimmunoprecipation assays the regulation of this complex after 18 h of melphalan treatment. As already reported by us, Bim was strongly associated with Mcl-1 and Bcl-2 in healthy nontreated MDN cells while it was weakly associated to Bcl-x L (Figure 3a) . After melphalan treatment, Mcl-1 immunoprecipitate showed that few Bim remained associated to Mcl-1. In particular, almost no BimS, the most potent isoform, was detected ( Figure 3b) . As both isoforms, BimL and S, were less affected by melphalan, this suggests that they were released from Mcl-1 complex, leading them able to exert their proapoptotic function, whereas free BimEL was probably made sensitive to caspase cleavage. Furthermore, we can hypothesize that the generated cleaved forms of BimEL are proapoptotic as previously described (Chen and Zhou, 2004) . Of interest, Bim immunoprecipitate from melphalantreated cells showed that Mcl-1L and S are weakly associated to Bim whereas the 26 kDa cleaved Mcl-1 is not complexed to it (Figure 3a) . In this way, Bim cannot be further neutralized by Mcl-1 and it is rendered free and able to initiate apoptosis. Moreover, the 26 kDa cleaved Mcl-1 could also exert its proapoptotic function and therefore amplify apoptosis. While the Bcl-x L /Bim complex was also totally disrupted by melphalan, Bcl-2/ Bim complex was not altered (Figure 3a) . This last result is in agreement with our recent study showing that the Bcl-2/Bim complex remains intact under apoptosis induced by growth factor starvation (Gomez-Bougie et al., 2004) .
Thus, Bim/Mcl-1 balance and Bim release, showed to be essential not only for apoptosis induction under growth factor deprivation, but appears to be a more general mechanism for cell death induction. Our study shows that a decrease in full-length Mcl-1 level, which initiated cell death, is associated with its cleavage by caspases, generating a proapoptotic protein with an impaired capacity to interact with Bim and therefore to neutralize it. Growing evidence is consistent with the notion that caspase cleavage of Bcl-2 family members (Clem et al., 1998; Snowden et al., 2003; Chen and Zhou, 2004; Herrant et al., 2004; Michels et al., 2004 Michels et al., , 2005 .
MM remains a fatal disease, which inevitably develops resistance to drugs such as melphalan. Thus, a promising therapeutical approach could be to disrupt the Mcl-1/Bim interaction by BH3 peptides or BH3 peptidomimetics. Even though, some small-molecule inhibitors were selected to disrupt BH3-Bcl-x L interaction, these chemicals could target multiple antiapoptotic Bcl-2 family members (Degterev et al., 2001) . Such molecules have already been tested in others cell systems (Degterev et al., 2001; Tzung et al., 2001) and in myeloma cells (Pei et al., 2003) .
Abbreviations BH, Bcl-2 homology (domain).
